Anbenitamab (KN-026) 是一种双特异性抗体，同时靶向人HER2的胞外结构域 II 和 IV。Anbenitamab 阻断配体依赖性和配体非依赖性 HER2 信号通路。Anbenitamab 的 IgG1 Fc 片段结合 FcRγIIIa 介导有效的抗体依赖性细胞介导的细胞毒性 (ADCC) 并抑制肿瘤细胞增殖。Anbenitamab 具有用于 HER2 阳性转移性乳腺癌 (MBC) 研究的潜力。
| 生物活性 | Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the humanHER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. TheIgG1Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breastcancer(MBC) research[1][2]. |
| IC50& Target[1] | |
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com